France's Abionyx to buy IRIS Pharma Holding, expand into ophthalmology (updated)

Abionyx Pharma SA

17/11/2021 18:36

(Adds detail)
    Nov 17 (Reuters) - French biopharmaceutical company Abionyx
Pharma  ABNX.PA  said on Wednesday it had signed a deal to buy
the owner of ophthalmological group IRIS Pharma.
    Abionyx said it would fully finance the deal, which values
IRIS Pharma Holding at 5 million euros ($5.66 million), through
a capital hike that aims to raise around the same amount.
    "Abionyx will have the means to develop a first class of
biomedicines to treat ophthalmological diseases - even the most
severe and rare ones," said Abionyx CEO Cyrille Tupin in a
statement, citing anticipated clinical programmes.
    Abionyx said the acquisition, which would make IRIS Pharma
an independent subsidiary, should help the group become a
specialist in ophthalmological biomedicine as well as kidney
diseases.
    It added that the capital increase prices Abionyx's shares
at 3.60 euros each and is already over three-quarters
subscribed.

($1 = 0.8832 euros)

 (Reporting by Sarah Morland
Editing by Chris Reese, Kirsten Donovan)
 ((sarah.morland@thomsonreuters.com; +48 58 769 65 92;))